Summary Delayed-type hypersensitivity (DTH) to Rauscher murine leukaemia virus (R-MuLV) encoded or induced determinants was induced in mice by three syngeneic R-MuLV-induced tumour cell lines, i.e. a myeloid tumour, RMB-1, an erythroid tumour, RED-1, and a lymphoid tumour, RLD-1. DTH to subcutaneously (s.c.) administered RMB-1 cells appeared on day 4, with a maximum DTH response on day 6 or 7. The induction of DTH could be prevented by intravenous (i.v.) pre-immunisation with R-MuLVinduced tumour cells several days before the s.c. immunisation. The three R-MuLV-induced tumour cell lines showed cross-reactivity in the DTH assay, whereas no cross-reactivity was found with syngeneic WEHI-3 cells. This indicates that the three R-MuLV-induced tumour cell lines share a virally encoded or induced antigenic determinant, which activates T-cells. When the RMB-1 cells used for immunisation had been cultured in medium supplemented with interferon-y (IFN-y) 
Immunological tumour-rejection depends on the presence of antigenic determinants on the tumour cells, which are not usually present on their normal counterparts. Such antigenic determinants may be induced by chemical, viral or physical agents and can also be found on spontaneously arising tumours (Halliday & Webb, 1969 ; Morton et al., 1969; Kripke, 1981; Galetto et al., 1985) . Cells transformed by RNA tumour viruses express virally encoded proteins, and so-called virus associated proteins (Nowinski, 1978; Rogers et al., 1984) . These neoantigens can induce antibody formation as well as cellular immune responses, such as cellular cytotoxicity and delayed-type hypersensitivity (DTH) (Levy & Leclerc, 1977) .
DTH responses can be easily elicited to various antigens, such as bacteria, viruses, xenogeneic red blood cells and contact sensitising _agents (reviewed by Crowle, 1975) .
Tumour cells can also induce DTH (Halliday & Webb, 1969; Hawrylko, 1980; Hoover et al., 1984) . DTH reactions are mediated by T-cells, particularly by the L3T4 positive helper T-cell subset (Mosmann & Coffman, 1987) . Evidence is increasing that Lyt-1 2-, L3T4+ T-cells, depending on the experimental conditions, can also mediate tumour rejection (Ozawa et al., 1986; Paul et al., 1987; Bookman et al., 1987) .
Several adjuvants have been used to increase the antitumour response, such as BCG (Hawrylko, 1980) and Corynebacterium parvum (Dye et al., 1981) . One could also increase the anti-tumour response by enhancing the immunogenicity of the tumour, for instance by using haptenated tumour cells (Suda et al., 1986) or by treatment with interferon, which is known to increase the expression of MHC-encoded antigens (Tanaka et al., 1986) .
In previous studies we reported about two R-MuLVspecific monoclonal antibodies (MAbs) raised against a RMuLV-induced myeloid tumour (Berends et al., 1988a, b, c) . One of the MAbs, which recognises virally encoded proteins on RMB-1 cells, was successfully used in immunotherapy. A striking difference was found between the effect of this MAb therapy in T-cell deprived nude mice and their euthymic littermates. This led us to suggest that a T-cell dependent anti-tumour immune response is involved (Berends et After having established that R-MuLV-induced tumour cells indeed evoke DTH, we investigated the specificity of this response, its suppression after i.v. pre-immunisation with irradiated tumour cells, and the effect of interferon-y (IFN-y) on the expression of the R-MuLV-induced tumour cell surface antigens and on the immunogenicity of RMB-1 cells as measured in the DTH assay.
Materials and methods

Mice
BALB/c (H-2d) and DBA/2 (H-2d) female mice, 4 weeks of age, were purchased from Bomholtgard (Ry, Denmark). BALB/c (H-2d) female mice, 4 weeks of age, were purchased from Harlan Olac Ltd (Bicester, UK). Other BALB/c (H-2d) female and male mice were bred at the Department of Cell Biology, Immunology and Genetics of the Erasmus University.
Cell lines Three R-MuLV-induced tumour cell lines were used: a myeloid tumour cell line of BALB/c origin (RMB-1), a lymphoid tumour cell line of DBA/2 origin (RLD-1), and an erythroid tumour cell line of DBA/2 origin (RED-1) (De Both et al., 1978 , 1981 , 1985 . The WEHI-3 immature macrophage cell line of BALB/c origin, originally described by Warner et al. (1969) , was used as a control. This cell line does not express R-MuLV antigens. All cell lines were cultured in RPMI 1640 tissue culture medium, supplemented with 10% fetal calf serum, glutamin (4mM), penicillin (lOOIUml-1) and streptomycin (l00 gml-1), in a humidified atmosphere with 5% CO2. IFN-y was supplied by Drs M. van Heuvel and I.J. Bosveld as culture supernatant from a Chinese hamster cell line with the amplified murine recombinant IFN-y gene (Dijkmans et al., 1985) containing 3 x 104IUml-1. As a control culture supernatant from the CHO12RO cell line was used (Stefanini et al., 1982) . When IFN-y was added to the tissue culture medium, it was supplemented to a final concentration of 100-150 IU ml-1.
Antigen density on RMB-J cells To quantitate the density of a R-MuLV-encoded surface antigen of RMB-1 cells, a Scatchard analysis was performed, using the specific MAb 1C5F5 that was previously described (Berends et al., 1988a) . Briefly, RMB-1 cells were incubated for 90 min at room temperature in a volume of 100 1l of Hanks' balanced salt solution (HBSS), supplemented with 20mM HEPES and 0.125% gelatin containing varying amounts (0.01-lOnM) of 125I-1C5F5. lodination of the MAbs was earlier described (Berends et al., 1988b (Figure 2 ).
Cross-reactivity between tumour-associated antigens on different R-MuLV-induced cell lines
To investigate whether the DTH reactive T-cells responding to the R-MuLV-induced tumour cell lines recognise a common (presumably viral) determinant we investigated the cross-reactivity in the DTH assay. Thus, BALB/c mice were s.c. immunised with 3 x 107 RMB-1 cells and challenged for DTH 7 days later with 6 x 106 RMB-1, RED-1 or RLD-1 cells. As a control groups of BALB/c mice were challenged with 6 x 106 DBA/2 spleen cells or with WEHI-3 cells. Effect of IFN-y on antigen-expression and DTH reactivity IFN-y is known for its enhancing effect on the expression of various antigens. We studied the effect of IFN-y on the expression of R-MuLV-induced antigens. To this end IFN-y was added to the culture medium of RMB-1 cells for 24 or 48 h. Stimulation of RMB-1 cells with IFN-y for 24 h caused a nearly two-fold increase in the amount of binding sites on RMB-1 cells detected by the binding of 1251-labelled-IC5F5 (Figure 5a) , and a slight decrease in affinity ( Figure Sb) . This coincided with a strong enhancement of DTH, P < 0.05 (Figure 6 ). After culture of RMB-l cells with IFN-y for 48 h the increase in R-MuLV antigen-expression was much smaller than in RMB-1 cells that had been cultured with IFN-y for 24 h. In this case also no enhancing effect in the DTH assay was found. Apparently the IFN-y induced increased expression of R-MuLV-encoded proteins by RMB-1 cells is only temporary. This increased antigenexpression was not due to an increase in the cell size (data not shown).
MHC class I and class II antigen expression Since it is possible that the enhanced DTH response is (partly) due to an increased MHC antigen expression on RMB-1 cells, we also studied the MHC class I and class II antigen expression, using the monoclonal antibodies Ml/42 (anti-H-2K) and M5/114 (anti-H-21-A). From Figure 7 it is clear that class I antigens are constitutively expressed by RMB-1 cells (Figure 7a ), whereas class II antigens are not (Figure 7b ). Moreover, after culturing RMB-1 cells for 24h in the presence of IFN-y, class I antigen expression was clearly enhanced, whereas class II antigen expression remained undetectable.
Discussion
This study shows that R-MuLV-induced tumour cell lines induce DTH in syngeneic mice. This T-cell dependent response is pronounced in the case of RMB-1 cells. The weak DTH responses evoked by RED-1 and RLD-1 cells were not significant above the background level, although they were highly reproducible. This correlates with the fact that the latter two cell lines differ from the RMB-1 cell line in that they are virus-producing, whereas RMB-1 is not. Moreover, RMB-1 cells grow s.c. only after inoculation of high numbers of cells whereas RED-1 and RLD-1 cells do even after s.c. inoculation of low numbers (unpublished results).
The maximum DTH response to RMB-1 cells was found 7 days after s.c. immunisation. This is in accordance with reports by others (Hawrylko et al., 1980) . DTH responses to histocompatibility antigens generally peak one or two days earlier.
All three different R-MuLV-induced cell lines could induce DTH, although the responses were not equally strong. We investigated whether DTH induced by s.c. immunisation with one cell line could be elicited by challenge with another RMuLV-induced cell line. Cross-reactivity was found in all combinations tested. The response was highest when RMB-1 cells were used for immunisation or challenge. The crossreactivity between RED-1 and RLD-1 cells was relatively weak, as could be expected in view of the weak DTH responses these cell lines evoke. Together the results suggest that the DTH response is directed to a common R-MuLVencoded or induced tumour-associated antigen, most clearly expressed on RMB-1 cells.
Even if tumours possess immunogenic determinants they can escape elimination by the immune system. The mechanisms involved could be the release of suppressive factors by the tumour cells (Mizel et al., 1980) , or the induction of suppressor cells (for a review see North, 1985) . Here we report the induction of suppression of the subsequent DTH response, by administration of a high dose of heavily irradiated tumour cells. Most probably the huge amount of tumour antigens leads to the induction of the state of suppression. Previously we investigated extensively the mechanism of suppression of the DTH response to H-2 and non-H-2 histocompatibility antigens after i.v. preimmunisation, which proved to be due to the induction of Ts cells. These Ts cells were found to be specific for the antigen(s) used for their induction (Van der Bianchi et al., 1984) . Despite this possibility of induction of antigen-specific Ts cells, it should be taken into account that factors released by the (irradiated) tumour cells might also give rise to the immunosuppression. The retroviral protein p15E should particularly be mentioned in this respect (Bendinelli et al., 1985) . When suppression can be induced by a huge amount of tumour antigens presented to the immune system, this phenomenon might play a role in clinical practice, since irradiation is frequently used in the therapy of malignant tumours, which leads to massive tumour reduction, and therefore to the appearance of large. amounts of tumourderived antigens in the bloodstream. This in turn could lead to suppression of the induction of an adequate immune response.
One approach to achieving tumour rejection is to prevent or block a possible immunosuppressive mechanism. Alternatively one might enhance the host's anti-tumour response using adjuvants, such as BCG (Hawrylko, 1980) and Corynebacterium parvum (Dye et al., 1981) . A third way would be the enhancement of tumour immunogenicity. Suda et al. (1986) reported increased anti-tumour immunity using haptenated tumour cells. Here we show that IFN-y can temporarily enhance the expression of tumour-specific antigens. Interestingly, in parallel the in vivo anti-tumour DTH response was enhanced ( Figure 6 ). On one hand, the enhanced DTH response could be caused by the increased expression of R-MuLV-encoded antigens. On the other hand, it is also possible that the increased MHC class I antigen expression accounts for the increased DTH response, since the immune recognition of syngeneic tumour cells may be MHC class I restricted similarly to DTH to minor histocompatibility antigens (Van der Kwast, 1980) . Various authors asked attention for the immunomodulating effects of interferons (for reviews see Krim, 1980; De Maeyer-Guignard & De Maeyer, 1985) . Interferons should exert their "effects via at least three mechanisms, i.e. direct cytotoxicity, increased MHC antigen expression on the tumour cells and increased host-mediated anti-tumour effects. Most studies on the effect of interferons on tumour immunogenicity focus on the increase of the expression of MHC antigens on the tumour cells (King & Jones, 1983; Green & Philips, 1986) . We found increased MHC class I antigen expression on the RMB-1 cells after culture with IFN-y, whereas class II antigen expression remained absent. The present study shows that IFN-y in addition enhances the expression of a. virally encoded or induced tumour antigen. A similar finding has recently been reported by Greiner et al. (1987) . They demonstrated the increased expression of a tumour-associated antigen on a human colon-xenograft after treatment with IFN-a. Accumulation of immature viral budding particles at the cell surface due to inhibitory action of IFN-a/f has been described before (Friedman et al., 1980) . Possibly, the effectiveness of MAb therapy of tumours can be improved by simultaneous treatment with a tumour antigen-enhancing lymphokine such as interferon.
